Quantum-Si incorporated QSI R2KPHARMA
Company Overview
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Recent Developments
- Dec 2025 Revenue of $2.44M (-20.3% YoY); net profit $-101.34M.
- Trailing 12 Months Year-on-year growth — revenue -69.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -69.40% |
Stock Price Performance
| 1 Year: | -34.53% |
| 6 Months: | -11.14% |
| 3 Months: | -27.05% |
| 1 Month: | +1.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 70.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QSI Quantum-Si incorporated R2KPHARMA | 0.77 | -1.54 | $152.32M | 0.00% | -52.16% | -46.38% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 254.00K | 205.00K | 223.00K | 457.00K | 622.00K | 787.00K | 842.00K | 591.00K | 552.00K | 258.00K |
| Gross Profit | - | - | - | - | - | - | 0 | 0 | 0 | 124.00K | 78.00K | 108.00K | 269.00K | 354.00K | 367.00K | 486.00K | 351.00K | 194.00K | 74.00K |
| Operating Income | - | -8.20M | -8.55M | -11.78M | -32.16M | -25.18M | -27.14M | -30.20M | -27.66M | -29.22M | -26.89M | -27.18M | -23.36M | -26.45M | -28.09M | -25.11M | -30.12M | -39.77M | -24.05M |
| Net Income | -10.31M | -8.20M | -8.56M | -11.78M | -35.70M | -18.09M | -35.17M | -32.41M | -31.71M | -23.61M | -25.57M | -24.73M | -19.47M | -23.10M | -25.31M | -19.19M | -28.84M | -35.70M | -21.67M |
| Diluted EPS | - | -1.53 | -1.60 | -2.13 | -0.97 | -0.13 | -0.25 | -0.23 | -0.23 | -0.17 | -0.18 | -0.17 | -0.14 | -0.16 | -0.18 | -0.11 | -0.16 | -0.17 | -0.10 |
| R&D Expense | - | 6.59M | 6.66M | 7.97M | 13.11M | 11.10M | 18.77M | 18.46M | 16.68M | 18.17M | 15.83M | 16.59M | 12.10M | 14.38M | 16.17M | 13.72M | 15.21M | 13.88M | 14.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 1.08M | 3.06M | 2.44M |
| Gross Profit | - | - | 0 | 0 | 488.00K | 1.60M | 1.15M |
| Operating Income | -36.62M | -36.69M | -96.91M | -123.84M | -111.17M | -108.58M | -116.10M |
| Net Income | -35.79M | -36.61M | -94.99M | -132.44M | -95.96M | -101.01M | -101.34M |
| Diluted EPS | -6.95 | -6.84 | -1.19 | -0.95 | -0.68 | -0.71 | -0.51 |
| R&D Expense | 28.10M | 27.55M | 46.58M | 72.06M | 67.03M | 59.64M | 53.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 40.59M | 503.23M | 391.49M | 298.25M | 247.87M | 245.61M |
| Total Equity | -92.14M | -125.10M | 0 | -159.72M | 477.03M | 358.71M | 271.62M | 215.42M | 220.23M |
| Cash & Equivalents | - | - | - | 36.91M | 35.78M | 84.32M | 133.86M | 49.24M | 21.64M |
| Total Liabilities | - | - | - | 4.50M | 26.19M | 32.78M | 26.63M | 32.45M | 25.38M |
| Current Liabilities | - | - | - | 2.75M | 11.53M | 15.71M | 11.61M | 18.19M | 23.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.71M | -32.57M | -66.81M | -90.56M | -94.04M | -87.80M | -94.72M |
| Investing Cash Flow | -1.24M | -461.00K | -450.94M | 137.19M | 143.43M | -32.67M | -28.32M |
| Financing Cash Flow | 18.22M | 37.01M | 516.62M | 1.91M | 149.00K | 35.88M | 95.42M |
| Capital Expenditure | -1.24M | -461.00K | -5.76M | -10.74M | -4.51M | -4.58M | -2.52M |
| Free Cash Flow | -31.95M | -33.03M | -72.58M | -101.30M | -98.55M | -92.38M | -97.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 45.1% | 52.3% | 47.3% |
| Operating Margin % | - | - | - | - | -10,274.6% | -3,550.6% | -4,766.0% |
| Net Margin % | - | - | - | - | -8,868.8% | -3,303.0% | -4,160.1% |
| ROE % | 28.6% | 22.9% | -19.9% | -36.9% | -35.3% | -46.9% | -46.0% |
| ROCE % | - | -97.0% | -19.7% | -33.0% | -38.8% | -47.3% | -52.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.81% | 7.58M | $5.91M |
| 2 | ARK Investment Management, LLC | 3.60% | 7.17M | $5.59M |
| 3 | Blackrock Inc. | 2.63% | 5.23M | $4.08M |
| 4 | Sumitomo Mitsui Trust Group, Inc. | 1.95% | 3.89M | $3.03M |
| 5 | Amova Asset Management Americas Inc | 1.95% | 3.89M | $3.03M |
| 6 | Millennium Management Llc | 1.57% | 3.13M | $2.44M |
| 7 | UBS Group AG | 1.29% | 2.56M | $2.00M |
| 8 | AQR Capital Management, LLC | 1.18% | 2.35M | $1.83M |
| 9 | Geode Capital Management, LLC | 1.12% | 2.24M | $1.74M |
| 10 | Jane Street Group, LLC | 1.08% | 2.14M | $1.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QSI
Dowdy Paula, director at Quantum-Si, buys $104,450 in stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTWNkdVNkdXItcHMzNjZ3Tl9YNy1tYnl3aUxVVF9DNHQ0b016dkJEdlh5cnJweGVKMTB6Z0Z1U0VGQUxKWm9LYmEzalJBV19pYXBOYk9ONVE5SmpiUjJNRUZiSnpYY2g0VUk0Nk9zZTlSRzdMRVVablFBQVRxekhoNzM4WTZBdlNfTFVITV…
Quantum-Si Inc (QSI) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNZ1VSd3pKVXJmUDJRMGhVRndVbXVCdU1CYm1COEZzMHVHb1JfM1BieVg4YllySXFjX0xacEN1dmpBcVJnZDd2TWtqclh4ZFd6Y3B6THZmQVg0YjZDbThjLTN4RFAtNUN0dHhxOG8yVWpjbmdEZHhVeS1Cb2xiWFd5TEs4ZGd6WngzdFlTNz…
Quantum-Si (QSI) Stock Falls on Q2 2026 Earnings | QSI Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOZjFNVktwbTlzRTRRSURZSl9yNlBCZWtjaW9NR0o2aWtaS09tV0xDSlNEY2FCc2p5Wnp1M091NHlUakRlbVBlcG5pX2ZlQnVPRkNyUmlnY00tUzVsYlh3c2FvMGFXZ0xZMjgtSGVVQmxYaFVCUXhsaE5mNEdIT3RNVm9rdkhibXJr?oc=5"…
Quantum-Si (NASDAQ: QSI) warned on Nasdaq $1.00 bid compliance - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPXzRYVjlxWHRhTS1yMTRrNHZwT0ZIYklqcTk3aDFTTUd0ZHFHZ0hPRFh2RGxwN1JlME1rbUxzMndTbW1CbFQ5Z25UY2RHYW8xS3kxYmh6cnJZNHlZWHEyTGROWkRodzdNRDVtemMwbTVPVUZrSXZFQWtsbFBoRlhoMUlYcTBrV3RDdE1sR0…
QSI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9PYUpUY0J5Y2J0c2RKZ25yWEtNaEdxMGE1Qjc5SmpIdjRQdXgtelhGZnVYMy1nd2NFU0s2dW5iTUJNTVhTbnpZSnFzREI1NXRZYTh3SXVEVWVtSVVvMzhWdHYxNjF0ckxVaEhWMzhBWEVBVWZSUnp0Zg?oc=5" target="_blank">QSI F…
Stock Traders Purchase Large Volume of Call Options on Quantum-Si (NASDAQ:QSI) - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeVozTi1mUTJvZFZWZUpuSGxfZFFmZFlnaGFRUjA0VWJPRVNFTnJZamxObDg4bXpwcEFBTUwzT3FTandYQ1g0Z0wwUnlrR3dwWVNFSzY2dkNpTFJkZnJPZnBTRHpjdmpZUjFBeW5HLXktYV9nNFBQcG1BVERlX182RHdxcHlIN3l4UWlCNU…
QSI — Frequently Asked Questions
What is the current share price of Quantum-Si incorporated (QSI)?
As of 2026-09-07 16:24 PDT, Quantum-Si incorporated (QSI) trades at $0.77 on NasdaqGM. Its 52-week range is $0.70 to $2.63.
What is the market capitalisation of QSI?
Quantum-Si incorporated (QSI) has a market capitalisation of $152.32M on NasdaqGM.
What is the P/E ratio of QSI?
QSI trades at a trailing price-to-earnings (P/E) ratio of -1.54. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.88.
What is the return on equity (ROE) of QSI?
QSI has a return on equity (ROE) of -46.38%. Its return on capital employed (ROCE) is -52.16%.
Is QSI a good stock to buy?
This page provides a data-driven analysis of Quantum-Si incorporated (QSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.